Logo image of ICLR

ICON PLC (ICLR) Stock Fundamental Analysis

NASDAQ:ICLR - Nasdaq - IE0005711209 - Common Stock - Currency: USD

145.21  -6.23 (-4.11%)

After market: 145.21 0 (0%)

Fundamental Rating

5

ICLR gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. ICLR has only an average score on both its financial health and profitability. ICLR scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make ICLR a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year ICLR was profitable.
In the past year ICLR had a positive cash flow from operations.
ICLR had positive earnings in each of the past 5 years.
Each year in the past 5 years ICLR had a positive operating cash flow.
ICLR Yearly Net Income VS EBIT VS OCF VS FCFICLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

ICLR's Return On Assets of 4.69% is fine compared to the rest of the industry. ICLR outperforms 76.79% of its industry peers.
ICLR has a better Return On Equity (8.31%) than 80.36% of its industry peers.
With a decent Return On Invested Capital value of 6.84%, ICLR is doing good in the industry, outperforming 75.00% of the companies in the same industry.
ICLR had an Average Return On Invested Capital over the past 3 years of 5.80%. This is significantly below the industry average of 12.87%.
The 3 year average ROIC (5.80%) for ICLR is below the current ROIC(6.84%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.69%
ROE 8.31%
ROIC 6.84%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ICLR Yearly ROA, ROE, ROICICLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

The Profit Margin of ICLR (9.56%) is better than 78.57% of its industry peers.
ICLR's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 14.73%, ICLR is in the better half of the industry, outperforming 76.79% of the companies in the same industry.
In the last couple of years the Operating Margin of ICLR has remained more or less at the same level.
ICLR's Gross Margin of 29.51% is on the low side compared to the rest of the industry. ICLR is outperformed by 75.00% of its industry peers.
In the last couple of years the Gross Margin of ICLR has remained more or less at the same level.
Industry RankSector Rank
OM 14.73%
PM (TTM) 9.56%
GM 29.51%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
ICLR Yearly Profit, Operating, Gross MarginsICLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICLR is destroying value.
The number of shares outstanding for ICLR has been reduced compared to 1 year ago.
ICLR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ICLR has an improved debt to assets ratio.
ICLR Yearly Shares OutstandingICLR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ICLR Yearly Total Debt VS Total AssetsICLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

ICLR has an Altman-Z score of 2.03. This is not the best score and indicates that ICLR is in the grey zone with still only limited risk for bankruptcy at the moment.
ICLR has a Altman-Z score (2.03) which is comparable to the rest of the industry.
The Debt to FCF ratio of ICLR is 3.06, which is a good value as it means it would take ICLR, 3.06 years of fcf income to pay off all of its debts.
ICLR has a better Debt to FCF ratio (3.06) than 80.36% of its industry peers.
ICLR has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
ICLR's Debt to Equity ratio of 0.36 is in line compared to the rest of the industry. ICLR outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 3.06
Altman-Z 2.03
ROIC/WACC0.89
WACC7.65%
ICLR Yearly LT Debt VS Equity VS FCFICLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 1.26 indicates that ICLR should not have too much problems paying its short term obligations.
ICLR has a Current ratio of 1.26. This is in the lower half of the industry: ICLR underperforms 78.57% of its industry peers.
ICLR has a Quick Ratio of 1.26. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
ICLR has a Quick ratio of 1.26. This is in the lower half of the industry: ICLR underperforms 73.21% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.26
ICLR Yearly Current Assets VS Current LiabilitesICLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.85% over the past year.
Measured over the past years, ICLR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.23% on average per year.
Looking at the last year, ICLR shows a small growth in Revenue. The Revenue has grown by 1.99% in the last year.
The Revenue has been growing by 24.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)2.85%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-8.07%
Revenue 1Y (TTM)1.99%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.26%

3.2 Future

The Earnings Per Share is expected to grow by 9.95% on average over the next years. This is quite good.
Based on estimates for the next years, ICLR will show a small growth in Revenue. The Revenue will grow by 4.86% on average per year.
EPS Next Y-0.25%
EPS Next 2Y5.45%
EPS Next 3Y7.76%
EPS Next 5Y9.95%
Revenue Next Year-0.3%
Revenue Next 2Y2.23%
Revenue Next 3Y3.72%
Revenue Next 5Y4.86%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ICLR Yearly Revenue VS EstimatesICLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ICLR Yearly EPS VS EstimatesICLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 10.58 indicates a reasonable valuation of ICLR.
Compared to the rest of the industry, the Price/Earnings ratio of ICLR indicates a rather cheap valuation: ICLR is cheaper than 98.21% of the companies listed in the same industry.
ICLR is valuated cheaply when we compare the Price/Earnings ratio to 28.88, which is the current average of the S&P500 Index.
ICLR is valuated reasonably with a Price/Forward Earnings ratio of 9.33.
ICLR's Price/Forward Earnings ratio is rather cheap when compared to the industry. ICLR is cheaper than 98.21% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.20, ICLR is valued rather cheaply.
Industry RankSector Rank
PE 10.58
Fwd PE 9.33
ICLR Price Earnings VS Forward Price EarningsICLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

ICLR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ICLR is cheaper than 98.21% of the companies in the same industry.
ICLR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ICLR is cheaper than 98.21% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.72
EV/EBITDA 9.01
ICLR Per share dataICLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

The decent profitability rating of ICLR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.69
EPS Next 2Y5.45%
EPS Next 3Y7.76%

More info and screens

0

5. Dividend

5.1 Amount

ICLR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICON PLC

NASDAQ:ICLR (5/1/2025, 4:37:00 PM)

After market: 145.21 0 (0%)

145.21

-6.23 (-4.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)07-22 2025-07-22/amc
Inst Owners97.89%
Inst Owner Change-0.69%
Ins Owners0.66%
Ins Owner ChangeN/A
Market Cap11.99B
Analysts82.22
Price Target213.44 (46.99%)
Short Float %2.33%
Short Ratio1.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.8%
Min EPS beat(2)-14.41%
Max EPS beat(2)-1.19%
EPS beat(4)0
Avg EPS beat(4)-3.99%
Min EPS beat(4)-14.41%
Max EPS beat(4)-0.04%
EPS beat(8)0
Avg EPS beat(8)-2.59%
EPS beat(12)4
Avg EPS beat(12)-1.62%
EPS beat(16)7
Avg EPS beat(16)-0.54%
Revenue beat(2)0
Avg Revenue beat(2)-4.14%
Min Revenue beat(2)-6.75%
Max Revenue beat(2)-1.54%
Revenue beat(4)0
Avg Revenue beat(4)-3.25%
Min Revenue beat(4)-6.75%
Max Revenue beat(4)-1.54%
Revenue beat(8)0
Avg Revenue beat(8)-2.73%
Revenue beat(12)0
Avg Revenue beat(12)-2.37%
Revenue beat(16)1
Avg Revenue beat(16)-1.54%
PT rev (1m)-16%
PT rev (3m)-25.7%
EPS NQ rev (1m)-1.92%
EPS NQ rev (3m)-12.26%
EPS NY rev (1m)-1.59%
EPS NY rev (3m)-8.48%
Revenue NQ rev (1m)-0.77%
Revenue NQ rev (3m)-3.06%
Revenue NY rev (1m)-1.22%
Revenue NY rev (3m)-2.46%
Valuation
Industry RankSector Rank
PE 10.58
Fwd PE 9.33
P/S 1.45
P/FCF 10.72
P/OCF 9.32
P/B 1.26
P/tB N/A
EV/EBITDA 9.01
EPS(TTM)13.72
EY9.45%
EPS(NY)15.57
Fwd EY10.72%
FCF(TTM)13.55
FCFY9.33%
OCF(TTM)15.58
OCFY10.73%
SpS100.31
BVpS115.35
TBVpS-37.41
PEG (NY)N/A
PEG (5Y)0.69
Profitability
Industry RankSector Rank
ROA 4.69%
ROE 8.31%
ROCE 8.66%
ROIC 6.84%
ROICexc 7.11%
ROICexgc 103.45%
OM 14.73%
PM (TTM) 9.56%
GM 29.51%
FCFM 13.51%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexcg growth 3Y-4.45%
ROICexcg growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 3.06
Debt/EBITDA 1.99
Cap/Depr 34.4%
Cap/Sales 2.03%
Interest Coverage 6.2
Cash Conversion 75.33%
Profit Quality 141.33%
Current Ratio 1.26
Quick Ratio 1.26
Altman-Z 2.03
F-Score8
WACC7.65%
ROIC/WACC0.89
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)2.85%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-8.07%
EPS Next Y-0.25%
EPS Next 2Y5.45%
EPS Next 3Y7.76%
EPS Next 5Y9.95%
Revenue 1Y (TTM)1.99%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.26%
Revenue Next Year-0.3%
Revenue Next 2Y2.23%
Revenue Next 3Y3.72%
Revenue Next 5Y4.86%
EBIT growth 1Y16.62%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year6.87%
EBIT Next 3Y7.95%
EBIT Next 5Y7.38%
FCF growth 1Y9.63%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y10.82%
OCF growth 3Y15.78%
OCF growth 5Y25.55%